Quantcast

Latest Endo Pharmaceuticals Stories

2014-02-27 20:22:56

/PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Ivan P. Gergel, executive vice president research & development and chief scientific officer, will be leaving the Company. Dr. Gergel will continue in his current role until March 31, 2014. MALVERN, Pa., Feb 27, 2013 Rajiv De Silva, president and chief executive officer of Endo, said, "I want to thank Ivan for his dedicated service and significant contributions to our R&D organization over...

2014-02-26 12:26:21

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin") were approved by Endo's shareholders. As previously announced, on November 5, 2013, Endo and Paladin entered into an arrangement agreement pursuant to which each of Endo and Paladin will be acquired by a new Irish holding company, Endo...

2014-02-21 12:24:58

MALVERN, Pa., Feb. 21, 2014 /PRNewswire/ -- Endo Pharmaceuticals, a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), announced today that it has reached a resolution of criminal and civil claims with the federal and participating state authorities and the District of Columbia regarding a previously disclosed investigation concerning past US sales, marketing and promotional practices related to Endo Pharmaceuticals Inc. product Lidoderm®. Under the agreement, the company...

2014-02-20 16:24:58

MALVERN, Pa., Feb. 20, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its fourth quarter 2013 financial results before the open of the U.S. financial markets on February 28, 2014 and members of its senior management team will host a conference call and webcast at 8:30 a.m. ET that day. Investors and other interested parties may call 866-515-2910 (domestic) or +1 617-399-5124 (international) and enter passcode 79916686. Please dial in 10 minutes prior to the...

2014-02-19 08:30:45

MALVERN, Pa., Feb. 19, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that it has completed its annual goodwill and in-process research and development (IPR&D) impairment analysis for 2013 and plans to record in fiscal 2013, a pre-tax, non-cash asset impairment charge of approximately $495 million, primarily related to goodwill attributable to the company's acquisition of American Medical Systems. During the fourth quarter of 2013, the company also...

2014-02-18 08:31:43

MALVERN, Pa., Feb. 18, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that the South African Competition Commission has completed its review and approved the merger of Endo and Paladin Labs without conditions in terms of section 14(1)(b) of the Competition Act (South Africa). In addition, the company announced that it has received regulatory approval under the Investment Canada Act. The Minister of Industry has completed a review of the transaction and...

2014-02-04 20:22:43

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/f3g6bf/pain_management) has announced the addition of the "Concise Analysis on the International Pain Management Treatment Markets" [http://www.researchandmarkets.com/research/f3g6bf/pain_management ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Pain management describes a particular set of drugs, analgesics, which...

2014-02-03 16:25:11

MALVERN, Pa., Feb. 3, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that it has completed the previously announced divestiture of HealthTronics to Altaris Capital Partners, LLC for an upfront cash payment of $85 million, subject to cash and other working capital adjustments. In addition, Endo received rights to additional cash payments of up to $45 million based on the future operating performance of HealthTronics for a total consideration of up to $130...

2014-02-03 08:27:32

MALVERN, Penn., Feb. 3, 2014 /PRNewswire/ -- -- Unique Generics Product Portfolio, Attractive Pipeline, Builds On Qualitest's Strength In Controlled Substances -- Transaction Expected To Be Immediately Accretive To Endo's Adjusted Diluted EPS Endo Health Solutions (Nasdaq: ENDP) today announced that its Qualitest subsidiary has completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash....

2014-01-29 16:28:52

MALVERN, Pa., Jan. 29, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today confirmed that the United States District Court for the District of Delaware ruled that United States Patent No. 5,464,864, Endo's patent covering frovatriptan, the active ingredient in FROVA(® )(frovatriptan succinate) tablets, is valid and infringed. The Court's decision prevents Mylan from marketing its generic version of FROVA(®) in the U.S. before Endo's patent expires November 8, 2015,...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related